Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07071051 · ClinicalTrials.gov registry record
Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
A clinical trial of Childhood Acute Lymphoblastic Leukemia and Childhood Lymphoblastic Lymphoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 15
- Enrollment target
- 1
- Study location
NCT07071051: Recruiting study of Childhood Acute Lymphoblastic Leukemia and Childhood Lymphoblastic Lymphoma, sponsored by Mayo Clinic.
NCT07071051 is a study of Childhood Acute Lymphoblastic Leukemia and Childhood Lymphoblastic Lymphoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07071051, a study of Childhood Acute Lymphoblastic Leukemia and Childhood Lymphoblastic Lymphoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
Primary Outcome
Frequency of coagulation changes in patients with Acute Lymphoblastic Leukemia (ALL) who receive Cal-peg as part of their treatment. Blood samples will be collected at baseline (pre-treatment: either before first dose or after at least 6 weeks from last Cal-PEG administration) and at 4-, 11-, 18-, and 39-- -days post-Cal-PEG administration (time points can be adjusted based on routine clinical testing within ± 4 days).
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-07-31 |
| Est. Completion | 2026-12-31 |
What NCT07071051 shows while recruiting
NCT07071051 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 2 conditions, with Childhood Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07071051 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07071051 about?
NCT07071051 is a clinical study titled "Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study". This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
What is the current status of trial NCT07071051?
This trial is currently recruiting. The enrollment target is 15 participants. The study started on 2025-07-31. Estimated completion is 2026-12-31.
What conditions does trial NCT07071051 study?
This clinical trial studies the following conditions: Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma.
What interventions are being tested in trial NCT07071051?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07071051?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07071051 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Childhood Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI